Halofuginone induces the apoptosis of breast cancer cells and inhibits migration via downregulation of matrix metalloproteinase-9

MEI LING JIN1, SUN YOUNG PARK1*, YOUNG HUN KIM1, GEUNTAE PARK3 and SANG JOON LEE2

1Bio-IT Fusion Technology Research Institute, 2Department of Microbiology, 3Institute for Research and Industry Cooperation, Pusan National University, Busan 609-735, Republic of Korea

Received September 2, 2013; Accepted October 14, 2013
DOI: 10.3892/ijo.2013.2157

Abstract. Halofuginone (HF) is extracted from Dichroa febrifuga, a plant used in traditional medicine. We report that the HF extract inhibits the growth of breast cancer cells and induces the generation of reactive oxygen species (ROS) and apoptosis, an important feature of potential anticancer agents. In addition, HF significantly reduces the migration and invasion of MCF-7 and MDA-MB-231 human breast cancer cells after 12-O-tetraecanoylphorbol-13-acetate (TPA) stimulation. As matrix metalloproteinase-9 plays a critical role in tumor metastasis, we analyzed its expression with the HF extract treatment. Western blot analysis and gelatin zymography showed that HF suppresses MMP-9 expression and activity concentration-dependently. HF also decreases the nuclear protein levels of nuclear factor kappa B (NF-κB) and c-fos (AP-1), critical transcription factors regulating MMP-9 expression through binding the MMP-9 promoter region. Luciferase assays showed that HF decreases TPA-induced MMP-9 promoter binding activities of NF-κB and AP-1. Taken together, these are the first results indicating that halofuginone may represent a promising new agent for breast cancer chemotherapy.

Introduction

Breast cancer is the predominant type of cancer among women and is the second leading cause of cancer-related mortality (1). Similar to other solid tumors, breast cancer is difficult to treat. Some traditional methods, such as chemotherapy, may cause strong side effects and drug resistance in patients. Therefore, there is continuing need to find novel, efficient and less toxic cancer therapeutic molecules. Natural products, such as plant-derived drugs, have played an increasing role in cancer treatment due to their fewer side effects and high efficacy.

The small molecule Halofuginone (HF) is an analog of quinazolinone alkaloid, a derivative of febrifugine originally isolated from the plant Dichroa febrifuga. It has been used as a drug, receiving certification from the US Food and Drug Administration in the early 1980s and is used for preventing coccidiosis infection in growing chickens and turkeys (2). In vitro, HF was first reported to inhibit collagen type I synthesis and extracellular formation via the reduction of matrix metalloproteinase-2 (MMP-2) (3). Halofuginone has also been shown to inhibit cancer cell growth and tumor metastasis in cell lines derived from hepatoma (4), melanoma (5) and multiple myeloma (6). In vivo, oral treatment with HF (at concentrations of 0.1-0.4 mg/kg per day) significantly reduced brain tumor growth and angiogenesis in a metastatic brain tumor model in rats (7). This study focused on the effect of HF on breast cancer based on its potent effects on various other types of tumor growth and metastasis.

Recently methods have been developed to prove the drug effectiveness as an anticancer compound. One of these strategies is to determine the ability and mechanism of novel anticancer agents to induce apoptosis in cancer cells. Therefore, various apoptotic pathways have been extensively investigated for many compounds to understand their cytotoxicity. A sensitive effector mechanism widely engaged in the control and modulation of apoptosis is cellular redox status, which is determined by the balance between the rates of generation and breakdown of reactive oxygen species (ROS) (8). ROS is a major regulator involved in apoptosis mediated through mitochondria. High levels of ROS in mitochondrial can induce several irreversible steps. First, free radicals may attack membrane phospholipids, causing mitochondrial membrane depolarization and the release of mitochondrial factors. This intrinsic apoptosis pathway is subsequently involved in the activation of caspases and DNA fragmentation (9).

Several novel anticancer agents extracted from plants, such as dryofragin (9), diallyl trisulfide (8) and levamisole (10) can inhibit various types of cancer cells by inducing apoptosis via
the generation of ROS and the disruption of mitochondrial transmembrane potential. *Centratherum anthelminticum* (L.) seeds induce apoptosis in breast cancer MDA-MB-231 cells, which is associated with ROS generation and downregulation of the mitochondrial proteins Bcl2 and Bcl-xl (11).

New anticancer agents have also been reported to control various other processes involved in the malignant transformation of cells, such as invasion and metastasis (12). The invasive behavior of cancer cells and their ability to metastasize to a distant location are multiple step processes associated with the detachment of cells from the original cancer, attachment to extracellular matrix (ECM) binding sites, degradation of the ECM and migration to target tissues (13). One of the critical steps involved in metastasis is the activity of MMPs that degrade a variety of ECM proteins (14). Of these MMPs, both MMP-2 and MMP-9 are the key enzymes that control the rate of cell invasion and metastasis (15,16). Therefore, the downregulation of MMP-2 and MMP-9 can be used as an important strategy for metastasis intervention and preventing cancer progression. Although these two gelatinases have similar properties, their gene expression is differentially and specifically regulated by distinct regulatory elements in their promoter regions (17). Compared to MMP-2, which is constitutively expressed, MMP-9 is strongly related to the malignant phenotype of various cancers and highly induced by a variety of stimuli, including epidermal growth factor (EGF), cytokines, UV radiation, oncogenes and 12-O-tetradecanoylphorbol-13-acetate (TPA) (18). Among these inducers, TPA can increase MMP-9 expression and secretion during breast cancer cell invasion through activating transcription factors including activator protein (AP-1) and nucleus factor κB (NF-κB), as its promoter region contains binding sites for these transcription factors (17).

Despite the diverse studies on the biological activities of HF, the potential of HF against breast cancer growth and invasion is poorly defined. The goal of this study was to evaluate the ability of HF to inhibit tumor growth and metastasis in the human breast cancer lines, MCF-7 and MDA-MB-231 cells. We also investigated the underlying pathways involved in inhibiting breast cancer cell growth, migration and invasion by HF. Furthermore, we show that HF induces the apoptosis of breast cancer cells and inhibits their migration via downregulating MMP-9 expression.

**Materials and methods**

**Reagents.** BD BioCoat™ Matrigel™ invasion chambers were obtained from BD Biosciences (San Jose, CA, USA). Cell culture media (RPMI-1640) and fetal bovine serum (FBS) were purchased from Gibco BRL (now part of Invitrogen Corp., Carlsbad, CA, USA). FuGENE-6 transfection reagent was purchased from Roche Applied Science (Indianapolis, IN, USA). Antibodies against MMP-2, MMP-9, phosphorylated p65, p65, phosphorylated IkBα, IkBα, c-fos and TBP were purchased from Cell Signaling Technology (Beverly, MA, USA). Halofuginone was purchased from Sigma-Aldrich (St. Louis, MO, USA).

**Cell culture.** Two human breast cancer cell lines, MCF-7 and MDA-MB-231 cells, were grown in RPMI supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin (Biochrom AG, Berlin, Germany). Cell cultures were grown to confluence and maintained in a humidified atmosphere at 37°C and 5% CO₂. The MCF-7 and MDA-MB-231 cells were incubated with fetal bovine serum-free medium for 24 h prior to the experiments. HF was then added to a final concentration in the range 1-200 nM.

**MTT cell viability assay.** The cell viability of MCF-7 and MDA-MB-231 cells was evaluated using a microculture (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-based colorimetric assay. Cells were incubated in 24-well plates at a density of 5x10⁴ cells per well. MTT solution (5µl of 5 mg/ml) was added to each well (final concentration, 62.5 µg/ml). After incubation for 4 h at 37°C in 5% CO₂, the supernatant was removed and the formazan crystals produced in the viable cells were solubilized in 150 µl of dimethylsulfoxide. The absorbance of each well was then read at 570 nm using a microplate reader (Wallac 1420, Boston, MA, USA).

**Measurement of intracellular ROS.** To evaluate intracellular ROS levels, cells were treated with CM-H$_2$DCFDA (Invitrogen, Paisley, UK), an indicator of general oxidative stress, for 1 h at 37°C under 5% CO₂. ROS are capable of oxidizing cleaved DCFH to DCF. The cells were then harvested and washed three times with PBS. Fluorescence intensity was measured using flow cytometry with an excitation wavelength of 488 nm and an emission wavelength of 525 nm. Data analyses were performed using CXP software 2.0 (Beckman Coulter, Brea, CA, USA).

**Analysis of mitochondrial membrane potential (Δψₘ).** The mitochondrial membrane potential (Δψₘ) of MCF-7 and MDA-MB-231 cells were determined by 5,5,6,6-tetramethyl-1,3,3-tetraethylbenzimidazolocarbocyanine iodide (JC-1) reduction. JC-1 is a sensitive indicator of Δψₘ, which causes its fluorescence to change from red to green. MCF-7 and MDA-MB-231 cells were stained with JC-1 and analyzed by subsequent flow cytometry. JC-1 red fluorescence, indicating intact Δψₘ, was excited at 488 nm and the emission detected using a 613±20-nm band pass filter. For each sample, 10,000 cells were acquired and analyzed by flow cytometry. Data were analyzed using the fluorescence intensity of the analyzed cell population.

**Cell cycle analysis and sub-G1 measurement.** We plated 1x10⁶ cells on 6-cm dishes for 24 h. The cells were incubated with 200 nM HF for 24 h, followed by the collection of cells by centrifugation. The pellets were mixed with 75% ethanol at -20°C overnight. The cells were then centrifuged and resuspended in 300 µl PBS containing 1% PI for 10 min at room temperature in the dark. The cells were immediately evaluated by flow cytometry. For each sample, 10,000 cells were acquired and analyzed by flow cytometry.

**Annexin V/PI dye staining.** Cells were seeded on 6-well plates at a density of 3x10⁵ cells/well. After SS treatment (50, 100 and 300 µg/ml) for 72 h, cells were stained with Annexin V and propidium iodide (Clontech, CA, USA) for 15 min at room temperature. The apoptotic index was determined by flow cytometry with FlowJo software. Triplicate independent experiments were performed.
Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL assay). The TUNEL assay is a common method for detecting DNA fragmentation that results from apoptotic signaling cascades. This assay relies on the presence of nicks in the DNA which can be identified by terminal deoxynucleotidyl transferase (TdT), an enzyme that will catalyze the addition of dUTPs that are secondarily labeled with a marker. TUNEL was performed on MCF-7 and MDA-MB-231 cells fixed for 10 min with 2% paraformaldehyde, washed twice in 0.1 M Tris buffer, fixed again for 1 min in aceton, washed and incubated for 1 h at 37°C with 1.5 µM fluorescein isothiocyanate-coupled dUTP (Boehringer-Mannheim) plus terminal deoxynucleotidyl transferase (TdT, 0.5 IU/µl; Boehringer-Mannheim) in 1X TdT buffer. After two more washes the cells were analyzed by flow cytometry. For each sample, 10,000 cells were acquired and analyzed by flow cytometry. Data analyses were performed with CXP software 2.0 (Beckman Coulter).

Gelatin zymography. To assess MMP-9 and MMP-2 gelatinase activity, MCF-7 and MDA-MB-231 cells were grown in 6-well plates. The cells were washed once with serum-free medium and placed in serum-free medium for 24 h prior to HF. Conditioned media was collected and prepared with standard SDS-gel loading buffer containing 0.01% SDS without β-mercaptoethanol and not boiled before loading. Prepared samples were then subjected to electrophoresis with 8% SDS polyacrylamide gels containing 0.1% gelatin. After electrophoresis, gels were wash twice with 150 ml 2.5% Triton-X-100 for 20 min at room temperature (to remove SDS) and then incubated in 150 ml incubation buffer (50 mM Tris-HCl, pH 8.0, 10 mM CaCl₂, 0.02% NaN₃) for 16 h at 37°C, stained with Coomassie brilliant blue R-250 and destained with destaining solution (20% methanol, 10% acetic acid and 70% water).

Cell invasion assay. The cell invasion assay was conducted using BD BioCoat™ Matrigel™ invasion chambers (BD Biosciences) according to the manufacturer’s instructions. Briefly, MDA-MB-231 cells (5x10⁴) and MCF-7 cells (5x10⁴) suspended in 500 µl of serum-free medium in the presence or absence of HF were seeded into upper chamber of filter inserts coated with growth factor containing Matrigel. After 1 h, 500 µl of serum-free medium containing 80 nM TPA was added to the bottom wells. Chambers were incubated at 37°C for 24 h, after which cells that had invaded the lower surface of the filter insert were methanol-fixed for 15 min and stained with 0.2% crystal violet for 15 min before being counted under the light microscope using a 10x objective.

Wound healing assay. To study the effects of HF on cell migration in vitro, a wound healing assay was performed using MCF-7 and MDA-MB-231 cells. These cells were seeded in 6-well plates and grown until the plates were 90% confluent. Cells were then serum-starved for 12 h. A linear wound was created in the confluent monolayer using a 200-ml pipette tip. Cells were then observed using a phase contrast microscope.

Preparation of nuclear extract. MCF-7 and MDA-MB-231 cells (3x10⁴) were washed three times with cold PBS and the cell pellets suspended in hypotonic buffer (Active Motif, Carlsbad, CA, USA) and incubated for 15 min on ice. Then 250 µl of detergent (Active Motif) was added to the cell extract and the sample was incubated on ice for 1 min. The extract was centrifuged at 13,000 rpm for 1 min at 4°C. After removing the 10-µl cytosolic protein-containing supernatant, nuclear proteins were extracted by adding complete 30 µl lysis buffer B (Active Motif) for 30 min at 4°C with occasional vortexing. After centrifugation at 13,000 rpm for 5 min at 4°C, the 28 µl supernatants were collected and stored at -70°C.

Western blot analysis. MCF-7 and MDA-MB-231 cells were harvested in ice-cold lysis buffer consisting of 1% Triton X-100, 1% deoxycholate and 0.1% sodium dodecyl sulfate (SDS). Protein content in the cell lysates was determined using the Bradford assay (Bio-Rad, Hercules, CA, USA). Total protein in each sample (50 µg) was resolved using 7.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE), transferred to a polyvinylidene difluoride membrane and incubated with the appropriate antibodies. The proteins were visualized using an enhanced chemiluminescence detection system (Amersham Biosciences, Piscataway, NJ, USA) with horseradish peroxidase-conjugated anti-rabbit or anti-mouse secondary antibodies. Western blotting was used to determine the level of MMP-9 (1:1,000 dilution), MMP-2 (1:1,000 dilution), P-65 (1:1,000 dilution), P-P65 (1:1,000 dilution), p-IκBα (1:1,000 dilution), c-fos (1:1,000 dilution), TBP (1:1,000 dilution) and tubulin (1:5,000 dilution). Images were acquired using an ImageQuant 350 analyzer (Amersham Biosciences, Little Chalfont, UK).

Luciferase assay. To determine promoter activity, we used a dual-luciferase reporter assay system (Promega, Madison, WI, USA). MDA-MB-231 cells were transfected with an NF-κB luciferase reporter plasmid or AP-1 luciferase reporter plasmid (Stratagene, Grand Island, NY, USA) using FuGENE-6 reagent (Roche Applied Science) according to the manufacturer’s instructions. Renilla luciferase control plasmid pRL-CMV (Promega) was co-transfected as an internal control of transfection efficiency. Cells were incubated with the indicated reagents for 1 h and then treated with TPA for 24 h. Luciferase was assayed with a dual-luciferase assay kit (Promega) according to the manufacturer’s instructions. Luminescence was measured with a GloMax™ 96 microplate luminometer (Promega).

Statistical analysis. All results were expressed as the mean ± SE. Each experiment was repeated at least three times. Statistical significance was measured between each treated group and analyzed by the paired Student’s t-test. Data with p<0.05 were considered statistically significant.

Results

HF is cytotoxic to breast cancer cells and induces the accumulation of intracellular ROS. To evaluate the effect of HF on the viability of breast cancer cells, MCF-7 and MDA-MB-231 cells were exposed to increasing concentrations of HF (from 25 to 800 nM) for 24, 48 and 72 h and the percentage of viable cells were determined using the MTT assay. HF decreased cell viability in a time- and concentration-dependent manner in MCF-7 and MDA-MB-231 breast cancer cells (Fig. 1A and B).
At 48 h, the IC₅₀ values of HF were found to be 200 nM in MCF-7 cells and 200 nM in MDA-MB-231 cells. Next, to determine whether intracellular ROS are involved in the cytotoxic effects of HF on these two cell lines, flow cytometry was used to detect changes in CM-H₂DCFDA fluorescence intensity in MCF-7 and MDA-MB-231 cells at 24, 48 and 72 h. Treatment with HF increased the intracellular production of ROS in a time-dependent manner, indicating that HF induced the accumulation of intracellular ROS in MCF-7 cells and MDA-MB-231 cells (Fig. 1C and D).

HF induces apoptotic cell death in breast cancer cells. To determine whether HF could induce apoptosis in breast cancer cells, cells were treated with 200 nM HA for indicated times and the apoptotic cell percentage was quantified by flow cytometry. HF increased the sub-G1 percentage of cells for two breast cancer cell lines compared to the control (Fig. 2A and B). To confirm this result, we also performed the TUNEL assay to detect the apoptosis levels induced by HF. The results showed that the percentage of apoptotic cell death significantly increased in HF-treated breast cancer cells (Fig. 1C and D).

HF induces apoptosis and disrupts mitochondrial membrane potential in breast cancer cells. To further evaluate the effect of HF on the induction of apoptosis, both breast cancer cell lines were incubated with 200 nM HF and then double-stained with Annexin V-FITC and PI, followed by quantitative flow cytometry analysis. After treatment with HF for 72 h, the cells presented features of early apoptosis in both cell lines (Fig. 3A and B). Compared to the control, the percentage of both early and late apoptotic cells increased with the addition of 200 nM HF. Based on our results, ROS may play a critical role in HF-induced apoptosis in both breast cancer cell lines. The mitochondria are a major source for ROS generation and are involved in ROS-related apoptosis. Disruption of mitochondrial transmembrane potential is related to mitochondrial dysfunction, which is linked to apoptosis and the loss of cell viability. To analyze whether mitochondria are involved in HF-induced apoptosis, we measured MMP changes using the JC-1 stain. When breast cancer cells were exposed to HF, the mitochondrial membrane potential strongly increased. These results indicate that HF can induce the loss of viability and apoptosis through enhancing intracellular ROS oxidative stress in MCF-7 and MDA-MB-231 breast cancer cells.

HF inhibits the migration and invasion of breast cancer cells. Cancer cells migration and invasion are critical steps of tumor metastasis. We tested cell motility with HF treatment in the wound-healing assay. TPA strongly increased MCF-7 and MDA-MB-231 cell migration by 24 h, but HF reduced migration levels by 24 h (Fig. 4A and B). In previous results, HF had inhibitory effects on the viability of breast cancer cells; therefore there was a possibility that the HF-mediated inhibition of invasion was a consequence of its cytotoxic effects. To
address this, we specifically examined the invasive behavior of breast cancer cell cultures in the presence or absence of HF in the transwell chamber assay. TPA induced cancer cell invasion (Fig. 4C and D); however, HF treatment decreased the invasive ability of both MCF-7 and MDA-MB-231 cancer cells. Taken together, our data suggest that HF inhibits the migration and invasion of MCF-7 and highly metastatic MDA-MB-231 cells in vitro.

HF decreases MMP-9 gene expression and activity. MMP-2 and MMP-9 are key proteins in the process of invasion and metastasis. Gelatin zymography was performed to investigate whether HF had inhibitory effects on TPA-induced MMP-2 and MMP-9 activity. Whereas MMP-2 activity remained unaffected, TPA-stimulated MMP-9 gelatinolytic activity was prevented by HF in both MCF-7 and MDA-MB-231 cancer cells (Fig. 5A and B). In agreement with the findings described above, HF treatment of the cells was found to decrease TPA-induced MMP-9 protein expression in both MCF-7 and MDA-MB-231 cancer cells (Fig. 5C and D).

HF decreases NF-κB and AP-1 gene expression and nuclear translocation. The promoter region of the MMP-9 gene contains binding sites for transcription factors, including AP-1 and NF-κB. Whether the inhibitory effect of HF on MMP-9 expression can occur through NF-κB and AP-1 activities was examined. Luciferase reporter assays performed on MCF-7 cells (transfected with NF-κB and AP-1 luciferase reporter plasmids) showed that TPA-enhanced NF-κB and AP-1 transcriptional activity was decreased by HA (Fig. 5F).
NF-κB is normally sequestered in the cytoplasm in an inactive form associated with its inhibitory protein, IκBα. Upon activation, the NF-κB p65 subunit is released to the nucleus to initiate target gene transcription as a result of IκBα degradation. AP-1 contains two subunits, c-fos and c-Jun, that can translocate to the nucleus when AP-1 is activated. In Western blot analysis, TPA increased the nuclear translocation of the NF-κB subunit p-p65 and the AP-1 subunit c-fos. In addition, TPA-stimulated NF-κB p65 and AP-1 c-fos nuclear translocation were reduced by HF treatment (Fig. 5E). In addition, HF was found to increase the TPA-induced reduction of cytoplasmic p-p65. Taken together, these results suggest that the inhibitory effect of HF on NF-κB and AP-1 signaling pathways can be attributed to its inhibition of p65 and c-fos nuclear translocation and the binding activity of transcription factors.

**Discussion**

Epidemiological studies have revealed an inverse association between the dietary intake of natural compounds and cancer risk (11,19). Various types of natural agents extracted from plants, including alkaloid compounds with anticancer activity, have recently been identified (20,21). One promising therapeutic candidate is Halofuginone, an orally available synthetic derivative of a quinazolinone alkaloid that has shown preclinical antitumor activity in various models, including human...
melanoma bone metastases (18,22). In the present study, we assessed the anticancer effects of HF and the mechanism of these effects.

The capability of anticancer drugs to induce the cellular apoptosis of cancer cells is an important property of cancer treatment (23,24). We observed a time-dependent apoptotic pattern with HF exposure that was similar between MCF-7 and MDA-MB-231 (Fig. 2A). Further evidence emerged from TUNEL assay results, which determined a strong elevation in apoptotic rate for both cell lines (Fig. 2).

In addition, we confirmed that HF induced apoptosis by causing the accumulation of ROS levels. ROS inducers as anticancer drugs have received considerable attention due to their selective effect on cancer cells while sparing normal cells (25). Emerging evidence suggests that ROS induced apoptotic cell death in cancer cells by causing mitochondrial membrane damage, resulting in a mitochondrial membrane potential disorder (26-28). We examined the mitochondrial membrane potential using a JC-1 stain and our results suggest that HF induces ROS generation and affects mitochondrial dynamics, inducing the dysfunction of mitochondrial membrane potential (Fig. 3B).

We observed an inhibitory effect of HF on TPA-induced migration and invasion in MCF-7 and MDA-MB-231 breast cancer cell lines. Accumulating evidence suggests that MMP-2 and MMP-9 expression are strongly implicated in breast cancer cell invasion (29). Effective anticancer agents involved in anti-invasion have demonstrated the ability to downregulate MMP-2 or MMP-9 expression. Our data reveal that HF inhibits TPA-induced MMP-9 expression, but does not influence MMP-2 expression levels in either MCF-7 or MDA-MB-231 breast cancer cells (Fig. 5). TPA treatment

Figure 4. HF affects TPA-stimulated migration and invasion in breast cancer cells. (A and B) The serum-starved cell monolayer was scratched with a pipette tip, pretreated with or without 200 nM HF for 1 h, then 200 nM TPA applied for 24 h. The results were observed under phase contrast microscope and photographed. (C and D) MCF-7 and MDA-MB-231 cells were treated with 200 nM HF for 24 h and the invasion ability of cells was quantified by counting the number of cells that invaded the underside of the porous polycarbonate membrane under a microscope.
strongly increased MMP-9 gelatinolytic activity, but did not similarly increase MMP-2 gelatinolytic activity. The result was consistent with a previous observation that only MMP-9 is induced with TPA and that MMP-9 plays a central role in the TPA-induced invasion of MCF-7 cells (16). MMP-9 regulates tumor progression and invasion on two levels, including activity and expression (30). MMP-9 is a critical enzyme required for degrading type IV collagen, a major component of the basement membrane. According to previous reports, inflammatory cytokines (IFN-γ), growth factors (HGF, EGF) and TPA stimulate MMP-9 by activating distinct intracellular signaling pathways in breast cancer cells (31,32). The
mechanism of MMP-9 expression induced by TPA is thus important for the development of a therapeutic experimental model of tumor metastasis.

To reveal the mechanisms of the TPA-induced signaling cascade involved in MMP-9 expression in MCF-7 cells, we investigated the effects of two transcription factors, NF-κB and AP-1 and their binding activity. It is well-known that MMP-9 expression can be influenced by AP-1 and NF-κB binding at its promoter region. The MMP-9 promoter contains DNA-binding sites for these transcription factors; thus, many differences in the promoter of these two MMPs could create different responses to TPA between the two MMPs (31). Therefore, the specific responsiveness of MMP-9 demonstrated that its downregulation by HF was changed through an upstream event. In agreement, we showed that HF reduced TPA-induced NF-κB and AP-1 transcriptional activity and translocation. These findings indicate that the reduction of MMP-9 and its transcription factors by HF might contribute to the prevention of TPA-induced invasive growth.

AP-1, which belongs to the bZIP group of DNA binding proteins, is comprised of homodimers or heterodimers via a combination of signaling events. This leads to the increasing activity of proteins that can directly regulate c-jun or c-fos expression (35). On the other hand, the transcription factor NF-κB forms a family of inducible transcription factors that regulates numerous genes associated with inflammation, cancer development and tumor invasion.

Accumulating reports have suggested that many biologically active natural phytochemicals such as curcumin, resveratrol and solasodigitigenin suppress NF-κB and AP-1 expression in cancer cells and eventually prevent cancer cell invasion (16,33,34). Exposure of cells to specific stimuli, including TPA, results in IKK complex activation, which in turn targets IκBα phosphorylation and degradation by the ubiquitin-proteasome machinery. This causes the NF-κB p65 subunit to translocate to the nucleus and bind the MMP-9 promoter to initiate MMP-9 gene transcription (36). In our results, HF reduced TPA-induced NF-κB p65 and AP-1 c-fos nuclear translocation through preventing IκBα phosphorylation. The NF-κB and AP-1 elements are centrally implicated in TPA-induced MMP-9 gene induction at two levels, including nuclear translocation and transcription activity. Therefore the inhibition of MMP-9 expression and its upstream elements can be a critical strategy involved in treating malignant tumors, including breast cancer.

In conclusion, the present study demonstrates that the natural compound HF exhibits effective antitumor properties. The observed antitumor activity inhibits the growth of cancer cells and induces apoptosis. In addition, our study provides evidence that HF can inhibit the migration and invasion of breast cancer cells through the downregulation of MMP-9 expression and its upstream transcription factors. Moreover, we revealed that the molecular mechanism by which HF inhibits MMP-9 expression is mediated through its suppressive effect on NF-κB and AP-1 activation. As tumor metastasis is often associated with poor prognosis and high mortality among breast cancer patients, the need to discover and develop new therapeutic strategies that target early tumor invasiveness or metastasis. In this regard, HF is a promising agent against breast cancer invasion and metastasis.

Acknowledgements
This study was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A3010601).

References


